Oligonol improves memory and cognition under an amyloid β25-35-induced Alzheimer's mouse model

Nutrition Research

Volumn 34, Issue 7, 2014, Pages 595-603

  Choi, Yoon Young ^a   Maeda, Takahiro ^b   Fujii, Hajime ^b   Yokozawa, Takako ^c   Kim, Hyun Young ^d   Cho, Eun Ju ^a   Shibamoto, Takayuki ^e  

^a Pusan National University   (South Korea)

^b Amino Up Chemical Co   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d Gyeongsang National University   (South Korea)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Memory; Mouse; Oligonol; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; MALONALDEHYDE; NEUROPROTECTIVE AGENT; NITRIC OXIDE; OLIGONOL; SODIUM NITRITE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (25-35); CATECHIN; PEPTIDE FRAGMENT; PHENOL DERIVATIVE; PLANT EXTRACT;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; IN VIVO STUDY; KIDNEY PARENCHYMA; LATENT PERIOD; LIPID PEROXIDATION; LIVER LEVEL; MALE; MAZE TEST; MEMORY; MEMORY DISORDER; MENTAL CAPACITY; MORRIS WATER MAZE TEST; MOUSE; NEUROPROTECTION; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PRIORITY JOURNAL; PROTEIN AGGREGATION; SPATIAL LEARNING; TASK PERFORMANCE; ANALOGS AND DERIVATIVES; ANIMAL; AWARENESS; BIOSYNTHESIS; BRAIN; COGNITION; COGNITION DISORDERS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; FRUIT; INSTITUTE FOR CANCER RESEARCH MOUSE; KIDNEY; LIVER; MEMORY DISORDERS; PHYTOTHERAPY; RECOGNITION;

MUS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AWARENESS; BRAIN; CATECHIN; COGNITION; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FRUIT; KIDNEY; LIPID PEROXIDATION; LIVER; MALE; MAZE LEARNING; MEMORY; MEMORY DISORDERS; MICE, INBRED ICR; NITRIC OXIDE; PEPTIDE FRAGMENTS; PHENOLS; PHYTOTHERAPY; PLANT EXTRACTS; RECOGNITION (PSYCHOLOGY);

EID: 84906790809     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2014.06.008     Document Type: Article

References (34)

1. Bennett D.A., Wilson R.S., Schneider J.A., Evans D.A., Mendes de Leon C.F., Arnold S.E. Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology 2003, 60:1909-1915.
2. Butterfield D.A., Reed T., Newman S.F., Sultana R. Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 2007, 43:658-677.
3. Fujii H., Nishioka H., Wakame K., Magnuson B.A., Roberts A. Acute, subchronic and genotoxicity studies conducted with oligonol, an oligomerized polyphenol formulated from lychee and green tea extracts. Food Chem Toxicol 2008, 46:3553-3562.
4. Noh J.S., Park C.H., Yokozawa T. Treatment with oligonol, a low-molecular polyphenol derived from lychee fruit, attenuates diabetes-induced hepatic damage through regulation of oxidative stress and lipid metabolism. Br J Nutr 2011, 106:1013-1021.
5. Nonaka, G. I., Sun, B., Yuan, L., Nakagawa, T., Fujii, H., & Surh, Y. J., (2004). Sulfur-containing proanthocyanidin oligomer composition and process for producing the same. International Patent Application No.: WO/2004/103988 A1.
6. Kitadate K., Homma K., Roberts A., Maeda T. Thirteen-week oral dose toxicity study of oligonol containing oligomerized polyphenols extracted from lychee and green tea. Regul Toxicol Pharmacol 2014, 68:100-146.
7. Lee Y.J., Choi D.Y., Han S.B., Kim Y.H., Kim K.H., Seong Y.H., et al. A comparison between extract products of Magnolia officinalis on memory impairment and amyloidogenesis in a transgenic mouse model of Alzheimer's disease. Biomol Ther 2012, 20:332-339.
8. Choi J.Y., Cho E.J., Lee H.S., Lee J.M., Yoon Y.H., Lee S. Tartary buckwheat improves cognition and memory function in an in vivo amyloid-β-induced Alzheimer model. Food Chem Toxicol 2013, 53:105-111.
9. Xu H., Wang H., Zhuang L., Yan B., Yu Y., Wei Z., et al. Demonstration of an anti-oxidative stress mechanism of quetiapine. Implications for the treatment of Alzheimer's disease. FEBS J 2008, 275:3718-3728.
10. Plate A.Y.A., Crankshaw D.L., Gallaher D.D. The effect of anesthesia by diethyl ether or isoflurane on activity o cytochrome P450 2E1 and P450 reductases in rat liver. Anesth Analg 2005, 101:1063-1064.
11. Bevins R.A., Besheer J. Object recognition in rats and mice: a one-trial non-matching to-sample learning task to study 'recognition memory'. Nat Protoc 2006, 1:1306-1311.
12. Montgomery K.C. A test of two explanations of spontaneous alternation. J Comp Physiol Psychol 1952, 45:287-293.
13. Morris R. Developments of a water-maze procedure for studying a spatial learning in the rat. J Neurosci Methods 1984, 11:47-60.
14. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95:351-358.
15. Schmidt H.H., Warner T.D., Nakane M., Förstermann U., Murad F. Regulation and sub cellular location of nitrogen oxide synthases in RAW264.7 macrophages. Mol Pharmacol 1992, 41:615-624.
16. Wong J.W., Hashimoto K., Shibamoto T. Antioxidant activities of rosemary and sage extract and vitamin E in a model meat system. J Agric Food Chem 1995, 43:2707-2712.
17. Yamada K., Nabeshima T. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol Ther 2000, 88:93-113.
18. Maurice T., Lockhart B.P., Privat A. Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction. Brain Res 1996, 706:191-193.
19. Stepanichev M.Y., Zdobnova I.M., Zarubenko I.I., Moiseeva Y.V., Lazareva N.A., Onufriev M.V., et al. Amyloid-beta (25-35)-induced memory impairments correlate with cell loss in rat hippocampus. Physiol Behav 2004, 80:647-655.
20. Chen Q.S., Kagan B.L., Hirakura Y., Xie C.W. Impairment of hippocampal long-term potentiation by Alzheimer amyloid β-peptides. J Neurosci Res 2000, 60:65-70.
21. Sun M.K., Alkon D.L. Impairment of hippocampal CA1 heperosynaptic transformation and spatial memory by beta-amyloid (25-35). J Neurophysiol 2002, 87:2441-2449.
22. Fang F., Liu G. Protective effects of compound FLZ on amyloid peptide-(25-35)-induced mouse hippocampal injury and learning and memory impairment. Acta Pharm Sin 2006, 27:651-658.
23. Yamanishi R. The anti-inflammatory effects of flavonol-rich lychee fruit extract in rat hepatocytes. PLoS One 2014, [in press].
24. Stepanichev M.Y., Onufriev M.V., Yakovlev A.A., Khrenov A.I., Peregud D.I., Vorontsova O.N., et al. Amyloid-β (25-35) increases activity of neuronal NO-synthase in rat brain. Neurochem Int 2008, 52:1114-1124.
25. Chabrier P.E., Demerle-Pallardy C., Auguet M. Nitric oxide synthases: targets for therapeutic strategies in neurological diseases. Cell Mol Life Sci 1999, 55:1029-1035.
26. Shibamoto T. Analytical methods for trace levels of reactive carbonyl compounds formed in lipid peroxidation systems. J Pharm Biomed Anal 2006, 41:12-25.
27. Ghoshroy M., Reed W., Balogh E., Moss M. Imaging inhibition of amyloid-beta protein aggregation in Alzheimer's disease by green tea epigallocatechin gallate (EGCG). Microsc Microanal 2012, 18(Suppl. 2):230-231.
28. Bastianetto S., Dumont Y., Quirion R. Catechins and resveratrol as protective polyphenols against beta-amyloid-induced toxicity: possible significance to Alzheimer's disease. Transworld Res Netw 2010, 145-154.
29. Yan J.J., Cho J.Y., Kim H.S., Kim K.L., Jung J.S., Huh S.O., et al. Protection against β-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol 2001, 133:89-96.
30. Bowman G.L., Kaye J.A., Moore M., Waichunas D., Carlson N.E., Quinn J.F. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 2007, 68:1809-1814.
31. Ujiie M., Dickstein D.L., Carlow D.A., Jefferies W.A. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 2003, 10:463-470.
32. Cheng Z., Zhang J., Liu H., Li Y., Zhao Y., Yang E. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption. Drug Metab Dispos 2010, 38:1355-1361.
33. Xu Y., Li S., Chen R., Li G., Barish P.A., You W., et al. Antidepressant-like effect of low molecular proanthocyanidin in mice: Involvement of monoaminergic system. Pharmacol Biochem Behav 2010, 94:447-453.
34. Fujii H., Sun B., Nishioka H., Hirose A., Aruoma O.I. Evaluation of the safety and toxicity of the oligomerized polyphenol oligonol. Food Chem Toxicol 2007, 45:378-387.